Similar result was reported that thiazolidinedione (TZD), targeting PPARγ, exerted the inhibitory effects on both osteoclastogenesis and osteoblastogenesis, and finally induced bone loss and increased higher risk of fracture in patients with type 2 diabetes [65, 66]. Here, PPARG is linked to type 2 diabetes mellitus.